en · de · es · fr · pt
sr9009-notes.peptides1126.com › Faq › Sr9009 Background And Mechanism — Evidence Review

Sr9009 Background And Mechanism — Evidence Review

By Editorial Desk · published 2025-11-19 · last reviewed 2026-01-10 · Faq

This is a working overview of reference standard, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2026-01-10. Anything still debated is marked as such rather than presented as settled.

SR9009 Background and Mechanism

Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.

Background and Research Status

Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.

REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic small-molecule REV-ERB agonistNot a hormone or natural product
Primary targetsREV-ERBα and REV-ERBβNuclear receptors involved in circadian and metabolic regulation
AppearanceWhite to off-white solidTypical for purified research samples
SolubilitySoluble in DMSO and ethanol; low water solubilityLaboratory solubility depends on solvent and purity
Common synonymsSR9009; StenabolicStenabolic is a colloquial name, not a formal chemical name

Handling Storage and Quality Control

Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.

Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.

Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.

Related pages on this site

Analytical Detection and Laboratory Handling

In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.

Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.

Analytical Detection and Storage

Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.

Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.

Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.

Supporting material

=== Impeachment of Sara Duterte === In December 2024, Duterte offered to join the defense team of his daughter, Vice President Sara Duterte, against her impeachment. On February 18, 2025, two weeks after the vice president was impeached by the House of Representatives, Duterte was listed as the legal counsel of his daughter in her Supreme Court petition to stop the impeachment from proceeding to trial.

Generative adversarial networks (GANs) are a generative modeling technique which consist of two neural networks—the generator and the discriminator—trained simultaneously in a competitive setting. The generator creates synthetic data by transforming random noise into samples that resemble the training dataset. The discriminator is trained to distinguish the authentic data from synthetic data produced by the generator. The two models engage in a minimax game: the generator aims to create increasingly realistic data to "fool" the discriminator, while the discriminator improves its ability to distinguish real from fake data. This continuous training setup enables the generator to produce high-quality and realistic outputs.

=== Khartoum massacre === In early June 2019, following al-Burhan's and Hemedti's visits to the Egyptian, UAE and Saudi leaders, the Sudanese Security Forces and Rapid Support Forces, including Janjaweed militias, led by al-Burhan and his deputy cracked down on peaceful protests in Sudan, starting with the 3 June Khartoum massacre. Human rights groups said that peaceful protesters were killed and about forty of the bodies were thrown in the river Nile, hundreds were tortured, violated and raped in the streets of Khartoum. Al-Burhan's talks with the opposition on forming a combined government were then cancelled. During the days that followed, the TMC arrested several of the opposition leaders. Iyad el-Baghdadi interpreted the decision-making by the TMC under al-Burhan's leadership as being strongly influenced by the general context of the Saudi, UAE and Egyptian leaders being afraid of democratic movements. Mahmoud Elmutasim, a political activist and doctor who graduated from the University of Khartoum, similarly stated that Saudi Arabia and the UAE are opposed to the existence of democracies in the Middle East, since if "the idea of democracy itself [should] ever take root, or become widespread in the Middle East," then it would constitute a threat to the governmental systems of Saudi Arabia and the UAE.

A story with Frazier Tharpe for GQ, published on June 2, 2025, started by stating that Clipse were unimpressed with the current state of mainstream hip-hop. The brothers gave Stove God Cooks and Future as exceptions. Pusha T lamented the feelings of loneliness and need to play "industry games" that came with his solo career, revealed that he was already becoming disillusioned with his former boss West during the 2019 recording sessions for Jesus Is King, and criticized West for his perceived character flaws. He also denied being a bad friend to West. The story of Clipse's dispute with Def Jam Recordings was told for the first time in this interview. Also included were comments about Drake suing Universal Music Group ("The suing thing is bigger than some rap shit. I just don't rate you.") and more details about the album: tracks "Mike Tyson", "POV", "F.I.C.O.", and features from Stove God Cooks and Lamar. After the release of "So Be It", GQ published a follow-up article (with unused excerpts from the interview) in which the song was discussed, including lyrics from Pusha T which diss Travis Scott. Another interview with Andre Gee for Rolling Stone was published on June 9. Clipse elaborated on their distribution deal with Roc Nation and announced a nationwide United States tour, planned to take place across twenty-five shows from August 3 to September 10.

=== 241Am === Americium-241 is a candidate isotope with much greater availability than 238Pu. Though 241Am has a half-life of 432 years, which is about five times longer than that of 238Pu and could hypothetically power a device for centuries, missions with more than 10 years were not the subject of the research until 2019. The power density of 241Am is only one-fourth that of 238Pu, and 241Am produces more penetrating radiation through decay chain products than 238Pu and needs more shielding. Its shielding requirements in a RTG are the third lowest: only 238Pu and 210Po require less. With a current global shortage of 238Pu, 241Am is being studied as RTG fuel by ESA and in 2019, UK's National Nuclear Laboratory announced the generation of usable electricity. An advantage over 238Pu is that it is produced as nuclear waste and is nearly isotopically pure. Prototype designs of 241Am RTGs expect 2–2.2 We/kg for 5–50 We RTGs design but in practical testing dropped to 1.3–1.9 We/kg. Americium-241 is currently used in small quantities in household smoke detectors and thus its handling and properties are well-established. However, it decays to neptunium-237, the most chemically mobile among the actinides.

Sources: en.wikipedia.org

Notes from published material

== Further reading == Press Conference by professor Samuel S. Epstein M.D. 1999-05-31 World Trade Organization (2000). Dispute Settlement Reports 1998. Cambridge University Press. p. 79. ISBN 0-521-78895-1. Galbraith, H. (December 2002). "Hormones in international meat production: biological, sociological and consumer issues". Nutrition Research Reviews. 15 (2). CABI Publishing: 293–314. doi:10.1079/NRR200246. PMID 19087409. M. Ellin Doyle. "Human Safety of Hormone Implants Used to Promote Growth in Cattle". National Cattlemen's Foundation. Archived from the original (Microsoft Word) on 7 May 2006. J. J. Kastner & R. K. Pawsey (29 November 2001). "Harmonising sanitary measures and resolving trade disputes through the WTO–SPS framework. Part I: a case study of the US–EU hormone-treated beef dispute" (PDF). Food Control. 13. Elsevier Science Ltd.: 49–55. doi:10.1016/S0956-7135(01)00023-8. Archived from the original (PDF) on 21 May 2004. Tim Josling; Donna Roberts & Ayesha Hassan (12 April 2000). "The Beef-Hormone Dispute and its Implications for Trade Policy" (PDF). Stanford University. Archived from the original (PDF) on 11 June 2007. Grace Skogstad (September 2001). "The WTO and Food Safety Regulatory Policy Innovation in the European Union". Journal of Common Market Studies. 39 (3): 485–505. doi:10.1111/1468-5965.00300. Christina L. Davis (2003). "Battles over Beef: The Beef Hormone Dispute". Food Fights Over Free Trade: How International Institutions Promote Agricultural Trade Liberalization. Princeton University Press. pp. 321–337. ISBN 0-691-11505-2.

=== 1. FC Lokomotive (since 2003–04) === In late 2003, the club was re-established by a group of fans as 1. FC Lokomotive Leipzig. The renewed side had to start in the lowest league, eleventh-tier 3. Kreisklasse, Staffel 2, in 2004–05. Even so, they continued to receive solidly enthusiastic fan support: their match against Eintracht Großdeuben's second team in the Leipzig Zentralstadion on 9 October 2004, broke the world record for lower-league attendance with 12,421 spectators. Thanks to a merger with SSV Torgau, the club could play in the seventh-tier Bezirksklasse Leipzig, Staffel 2, in 2005–06. Finishing this league as champions, the team qualified for the sixth-tier Bezirksliga. In 2006, 1. FC Lokomotive Leipzig also played a friendly match against FC United of Manchester (4–4) and qualified for the 2006–07 Landespokal by winning the Bezirkspokal. 1. FC Lokomotive Leipzig finished as champions of their group and were promoted to the fifth-tier Landesliga Sachsen Group for the 2007–08 season. The club finished second to Erzgebirge Aue and missed out on direct promotion to the NOFV-Oberliga Süd by two points in the 2007–08 season. It still had the chance to regain Oberliga status through a relegation play-off with Schönberg, winning the first leg 2–1 at Schönberg. In the return leg, in front of almost 10,000 spectators, the club lost 0–1 but still gained Oberliga promotion via the away goals rule. 1. FC Lokomotive Leipzig finished the Oberliga in third place in 2008–09, 12th in 2009–10, and eighth in 2010–11. 1.

Chlorosis, a condition where a plant cannot produce sufficient chlorophyll. A lack in copper, iron, manganese, or zinc can cause chlorosis. Boron deficiency, a condition where a plant's ability to reproduce, grow, and create stem cells is inhibited. Molybdenum deficiency, a condition where a buildup in nitrate because of a lack of nitrogenase production causes leaf yellowing, necrosis, and premature germination.

Looksmaxxing (; LUUKS-MAK-sing) is an online self-improvement practice from the manosphere focused on maximizing one's physical attractiveness. The term is a neologism which was coined on incel message boards in the 2010s. Previously, the phrase had limited usage on obscure internet forums of the incelosphere, but was popularized on TikTok by primarily male content creators in the 2020s. Based on white supremacy, the term has commonly been associated with the black pill ideology, which espouses that female sexual selection is primarily based on external physical qualities such as height and facial attractiveness, while qualities such as kindness and personality are ignored or even cause rejection. Looksmaxxing methods range from benign practices such as skincare routines and gym use, to more extreme interventions such as invasive cosmetic surgery and injection of anabolic steroids, human growth hormone and other peptides. Commentators generally criticize the concept as being judgemental and harmful to its practitioners ("looksmaxxers"). Communities and influencers associated with the practice are described as rating individual's appearance without concern for their overall well-being which can lead to negative mental health outcomes such as body dysmorphia and suicidal ideation. The increasing popularity of the concept has also led to concerns over its potential to promote hegemonic masculinity.

Sources: en.wikipedia.org

Background from the literature

==== Power generation ==== The unique properties of sCO2 present advantages for closed-loop power generation and can be applied to power generation applications. Power generation systems that use traditional air Brayton and steam Rankine cycles can use sCO2 to increase efficiency and power output. The relatively new Allam power cycle uses sCO2 as the working fluid in combination with fuel and pure oxygen. The CO2 produced by combustion mixes with the sCO2 working fluid. A corresponding amount of pure CO2 must be removed from the process (for industrial use or sequestration). This process reduces atmospheric emissions to zero. sCO2 promises substantial efficiency improvements. Due to its high fluid density, sCO2 enables compact and efficient turbomachinery. It can use simpler, single casing body designs while steam turbines require multiple turbine stages and associated casings, as well as additional inlet and outlet piping. The high density allows more compact, microchannel-based heat exchanger technology. For concentrated solar power, carbon dioxide critical temperature is not high enough to obtain the maximum energy conversion efficiency. Solar thermal plants are usually located in arid areas, so it is impossible to cool down the heat sink to sub-critical temperatures. Therefore, supercritical carbon dioxide blends, with higher critical temperatures, are in development to improve concentrated solar power electricity production.

Witnesses included FDA officials. They looked into several areas: the delay in reporting by Menu Foods, the lack of federal inspections of pet food facilities, and incomplete reporting by the FDA since the start of the recall. During the hearing Senators Durbin and Byrd criticized the government's response during the recall. Durbin specifically criticized the lack of any regular inspection practices or quality control with regards to pet food safety. Senator Kohl criticized the FDA's communication to the public about recalled foods, noting that volunteer websites had more detailed and easier-to-access information about the extent of the problem and which specific foods are of concern than FDA's online resources which Kohl said was contradictory of itself at times, and which the FDA official giving testimony admitted to being difficult to navigate. On 18 April 2007, Senator Durbin and Representative DeLauro met with US FDA Commissioner von Eschenbach to discuss the additional rice protein recalls and learned that the Chinese government was blocking outside attempts to investigate the contamination. In response, they sent a letter to Zhou Wenzong, China's Ambassador to the United States saying in part that "contaminated batches of wheat gluten and rice protein responsible for these events were imported from China" and that "no level of melamine should be found in pet or human food" and asking for visas for inspectors from the United States.

=== Preclinical === EB-002 (EB-373; psilocin prodrug) – non-selective serotonin receptor agonist and psychedelic hallucinogen [16] Midomafetamine (MDMA; ecstasy) microneedle patch – serotonin–norepinephrine–dopamine releasing agent, weak serotonin 5-HT2 receptor agonist, and entactogen [17] Nerinetide (NA-1; Tat-NR2B9c) – PDZ domain inhibitor [18] OV-4041 – potassium–chloride-cotransporter agonist [19] PSIL-025 – serotonin 5-HT1 receptor modulator [20]

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.

How does SR9009 work?

It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.

Is SR9009 proven to improve human performance?

No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.

What is SR9009?

It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.

Network